Johnson & Johnson (NYSE:JNJ) Shares Sold by Wealthspire Advisors LLC

Wealthspire Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 90,480 shares of the company’s stock after selling 6,223 shares during the quarter. Wealthspire Advisors LLC’s holdings in Johnson & Johnson were worth $13,085,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its holdings in shares of Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson during the third quarter worth approximately $209,000. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the third quarter valued at approximately $213,000. Swedbank AB increased its stake in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Finally, Hamlin Capital Management LLC raised its holdings in Johnson & Johnson by 15.3% during the third quarter. Hamlin Capital Management LLC now owns 982,593 shares of the company’s stock worth $159,239,000 after purchasing an additional 130,305 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Up 1.5 %

Shares of NYSE:JNJ opened at $166.13 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $399.98 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm’s 50-day simple moving average is $149.72 and its 200-day simple moving average is $155.92.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.29 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.